ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

biogen netherlands b.v. - dimetylfumarát - roztrúsená skleróza - imunosupresíva - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

takeda pharma a/s - ferumoxytol - anemia; kidney failure, chronic - iné prípravky protianemický - rienso je indikovaný na intravenóznu liečbu anémie s nedostatkom železa u dospelých pacientov s chronickým ochorením obličiek (ckd). diagnóza nedostatok železa musí byť založené na príslušné laboratórne skúšky (pozri časť 4.

ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - kolorektálne novotvary - antineoplastické činidlá - liečba metastatického kolorektálneho karcinómu (mcrc).

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

aachen resonance gmbh pauwelsstrasse 19 52074 aachen nemecko -

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

siemens shenzhen magnetic resonance ltd. siemens mri center, gaoxin c. ave., 2nd hi-tech industrial park 518057 shenzhen Čína -

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

siemens shenzhen magnetic resonance ltd. siemens mri center, gaoxin c. ave., 2nd hi-tech industrial park 518057 shenzhen Čína -

ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinálne stromálne nádory - iné antineoplastické činidlá, protein kinase inhibítory - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

siemens shenzhen magnetic resonance ltd. siemens mri center, gaoxin c. ave., 2nd hi-tech industrial park 518057 shenzhen Čína -

ইউরোপীয় ইউনিয়ন - স্লোভাক - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastické činidlá - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

শ্লোভাকিয়া - স্লোভাক - ŠÚKL (Štátny ústav pre kontrolu liečiv)

siemens shenzhen magnetic resonance ltd. siemens mri center, gaoxin c. ave., 2nd hi-tech industrial park 518057 shenzhen Čína -